Controlled trial of methotrexate versus CH-1504 in the treatment of rheumatoid arthritis.

Abstract

OBJECTIVE:

To investigate the clinical efficacy, safety, tolerability, and toxicity profile of a metabolically stable antifolate, CH-1504, compared to methotrexate (MTX) in the treatment of rheumatoid arthritis (RA).

METHODS:

A 24-week open-label trial of MTX and CH-1504 was performed in 20 patients with RA.

RESULTS:

Improvements in clinical and laboratory indicators were observed in both study groups. Improvement in the CH-1504 group was greater than in the MTX group. Both treatments were generally well tolerated; however, the liver function test abnormalities and gastrointestinal related adverse events expected with this class of medication were not seen with CH-1504.

CONCLUSION:

CH-1504 appears to be clinically efficacious and may possess a superior safety and tolerance profile compared to MTX.

• Authors: Oswaldo Castaneda, M Gopal Nair
• Journal: The Journal of rheumatology (J Rheumatol) Vol. 33 Issue 5 Pg. 862-4 (May 2006) ISSN: 0315-162X [Print] Canada
• PMID: 16652417 (Publication Type: Comparative Study, Controlled Clinical Trial, Journal Article)

Chemical References

• 4'-methylene-5,8,10-trideazaaminopterin
• Antirheumatic Agents
• Folic Acid Antagonists
• Aminopterin
• Methotrexate

Topics

• Adult
• Aged
• Aminopterin (adverse effects, analogs & derivatives, pharmacology, therapeutic use)
• Antirheumatic Agents (adverse effects, pharmacology, therapeutic use)
• Arthritis, Rheumatoid (drug therapy, physiopathology)
• Female
• Folic Acid Antagonists (adverse effects, pharmacology, therapeutic use)
• Gastrointestinal Tract (drug effects, physiopathology)
• Humans
• Liver (drug effects, physiopathology)
• Liver Function Tests
• Male
• Methotrexate (adverse effects, pharmacology, therapeutic use)
• Middle Aged